SYSTEMATIC REVIEW

BMC Neurology



Epidemiology and clinical implications of atrial fibrillation among stroke patients in Ethiopia: a comprehensive systematic review and meta-analysis



Mohammed Mecha^{1*}, Yordanos Sisay^{2*} and Tsegaye Melaku^{3*}

Abstract

Background Atrial fibrillation (AF) is a significant risk factor for stroke, imposing a substantial burden on healthcare systems. While studies have shown varying AF prevalence among stroke patients, limited pooled data exists in low-resource settings like Ethiopia. This hinders our understanding of the problem's extent and limits effective prevention and management strategies. Therefore, this systematic review and meta-analysis aimed to determine the pooled prevalence of atrial fibrillation among stroke patients in Ethiopia.

Methods The searches were carried out in electronic databases such as PubMed/MEDLINE, EMBASE, Science Direct, Web of Science, and Google Scholar. Observational study designs were selected, and studies published until 30 November 2023 addressing the prevalence of atrial fibrillation among stroke patients were identified. Endnote citation manager software version X₉ for Windows was used to collect and organize the search outcomes and remove duplicate articles. The relevant data were extracted from the included studies using a format prepared in Microsoft Excel and exported to STATA 18.0 software for the outcome measures analyses and subgrouping.

Results Twenty-three research articles were included in the final analysis. These studies evaluated a total of 4,544 stroke patients, of whom 529 were diagnosed with atrial fibrillation (AF). The overall pooled prevalence of AF among stroke patients was 13% [95% CI: (10%, 17%)]. Subgroup analysis by region revealed that the highest pooled prevalence of AF was 16% [95% CI: (8%, 25%)] in the Amhara region, followed by the Oromia region at 15% [95% CI: (7%, 23%)]. In Addis Ababa City, the pooled prevalence of AF among stroke patients was 11% [95% CI: (7%, 15%)]. The Tigray region reported a pooled prevalence of 9% [95% CI: (6%, 11%)]. However, one study from the Southern Nations, Nationalities, and Peoples' Region reported a lower prevalence of AF among stroke patients at 7% [95% CI: (3%, 11%)].

*Correspondence: Mohammed Mecha Mohammed.mecha@yahoo.com Yordanos Sisay yordusisay@gmail.com Tsegaye Melaku tsegish.melaku@gmail.com

Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creativecommons.org/licenses/by-nc-nd/4.0/.

Conclusion In summary, the study revealed that AF is prevalent among stroke patients in Ethiopia, with regional differences in prevalence. The high prevalence of AF emphasizes the necessity for effective management strategies to prevent recurrent strokes.

Systematic review registration number PROSPERO CRD: CRD42024581661.

Keywords Atrial fibrillation, Ethiopia, Stroke, Systematic review, Meta-analysis

Introduction

Atrial fibrillation (AF), a common cardiac arrhythmia characterized by irregular and rapid heartbeats, significantly impacts stroke risk and outcomes. As the most prevalent sustained cardiac arrhythmia [1-3], AF poses a major global health threat. Its association with stroke, a leading cause of mortality and morbidity worldwide, underscores its clinical significance [4, 5]. The literature extensively documents the clinical impact of AF among stroke patients. Numerous studies highlight AF's substantial contribution to stroke incidence, severity, and outcomes [5-8]. It increases the risk of stroke by nearly five times, and projections indicate a further rise in this risk, potentially reaching up to 25 [9]. Epidemiological evidence consistently supports AF as a leading cause of ischemic stroke, particularly in older adults [10, 11]. Beyond its impact on stroke incidence and severity, AF is also associated with a higher risk of recurrent stroke and other cardiovascular events. Patients with AF are more likely to experience recurrent strokes, exacerbating the overall burden of AF-related stroke [12–14].

The economic burden of AF-related stroke is substantial, with significant healthcare costs associated with the management and treatment of stroke patients with AF. These costs encompass hospitalization, rehabilitation, long-term care, and medications [15-17]. Moreover, the burden extends beyond the individual patient, affecting families and caregivers who often face emotional, financial, and social challenges in caring for stroke survivors with AF [18, 19].

In low- and middle-income countries like Ethiopia, the impact of AF-related stroke may be particularly pronounced due to limited healthcare resources. Inadequate access to specialized care, diagnostic tools, and medications can further exacerbate the outcomes of AF-related stroke in these settings [20]. Given the significant burden of atrial fibrillation among stroke patients, there is a critical need for research and healthcare interventions to improve management and outcomes. This includes enhancing stroke prevention strategies, optimizing AF management for stroke patients, and improving access to quality care for individuals with AF in Ethiopia and similar settings [14, 20–23].

The complex interplay between AF and stroke underscores the urgent need for effective prevention and management strategies. Understanding the prevalence of AF among stroke patients is essential for comprehending the burden of AF-related stroke and developing targeted interventions [24, 25]. It is a complex condition influenced by a multitude of factors that can be categorized as either modifiable or non-modifiable. Non-modifiable risk factors include age, with the risk increasing significantly after the age of 60; genetics, where a family history of AF can elevate the risk; and structural abnormalities of the heart, such as enlarged chambers or valve issues [26–28].

Modifiable risk factors, which individuals can change or manage to lower their risk of AF, encompass high blood pressure, heart disease (including coronary artery disease and heart failure), and certain surgical procedures or illnesses (e.g., pneumonia). Additional modifiable factors include obesity (particularly when associated with hypertension or heart disease), smoking, excessive alcohol consumption, chronic stress and anxiety, sleep apnea, and stimulant intake (e.g., caffeine). Certain medications, such as beta-blockers and calcium channel blockers, can also help mitigate the risk [26, 27, 29]. It is crucial to recognize that the risk of AF often stems from a combination of these factors. Individuals with multiple risk factors are at greater risk overall. By actively addressing modifiable risk factors through lifestyle changes and medical interventions, individuals can significantly decrease their likelihood of developing atrial fibrillation.

Existing studies have demonstrated a high prevalence of AF among stroke patients, emphasizing its significant burden on the healthcare system The prevalence of AF among stroke patients varies widely across studies, and there is a need to synthesize the available evidence to obtain a more accurate estimate. However, the availability of pooled data on AF prevalence in low-resource settings, such as Ethiopia, remains limited. This lack of comprehensive data hinders our understanding of the true extent of the problem and limits the development of effective prevention and management strategies. To address this knowledge gap, this systematic review and meta-analysis aimed to determine the pooled prevalence of atrial fibrillation among stroke patients in Ethiopia. By providing a comprehensive overview of the available evidence, this study seeks to inform healthcare policy and guide future research efforts to improve the management of AF-related stroke in the Ethiopian context.

Methods

Reporting

This systematic review and meta-analysis were based on the recommended methodology and followed the Preferred Reporting Items for Systematic Review and Meta-Analysis for (PRISMA) 2020 [30] (Fig. 1) and the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guideline [31]. The results were reported based on the PRISMA statement and the article screening and selection process were demonstrated through a PRISMA flow diagram (Supplementary file 1). It was registered with the International Prospective Register of Systematic Reviews (PROSPERO) (registration number: *CRD42024581661*).

Search strategy

We used different electronic biomedical databases and indexing services such as Google Scholar, Science Direct, Web of Sciences, EMBASE, and PubMed/MEDLINE to explore relevant studies. Potentially applicable studies were manually searched for using a list of references from the retrieved studies. Only studies published in English until 30 November 2023, were considered for inclusion in this review. The Condition, Context, and Population (CoCoPo) framework was used to develop an appropriate search strategy for database searching. The search strategy included keywords or indexing terms related to AF. The search terms used were "magnitude", "prevalence", "epidemiology", "burden" "atrial fibrillation", "stroke", "Cerebrovascular events", "Cerebrovascular accidents", "Ethiopia" (Supplementary file 2). Studies that assessed the prevalence of AF were considered relevant. The search strategy was based on keywords using "Medical Subjects Headings (MeSH)" and "All fields" by linking "AND" and "OR".

Data extraction and quality assessment

Endnote citation manager for Windows Version X_9 (Thomson Reuters, Philadelphia, PA, USA) was used to import the retrieved studies, and duplicates were removed. Two independent reviewers (MM and TM) screened all the articles for the eligibility criteria. Reviewers began by screening the abstract and title, followed by full-text screening. The quality of the articles was




Fig. 1 PRISMA flowchart showing the search and study selection strategy

assessed by using the Newcastle-Ottawa Quality Assessment Scale (adapted for cross-sectional studies) [32] (Supplementary file 3). Disagreements were resolved by inviting a third investigator to participate (YS). The articles were critically appraised by the following criteria from the tool: Representativeness of the sample (1 score maximum), sample size (1 score maximum), non-respondent (1 score maximum), ascertainment of exposure (2 score maximum), Comparability of outcome based on study design (2 score maximum), outcome assessment (2 score maximum) and Statistical analysis (1 score maximum). All the included studies assessed through the tool with a score of ≥ 5 was included in this systematic review and meta-analysis. After the quality rating, no study was dismissed. Microsoft Excel with a standardized extraction format was used by two investigators for the data extraction. The Excel spreadsheet includes the first author's name, sample size, publication year, region, study design, and prevalence of AF.

Eligibility criteria (inclusion and exclusion criteria)

The following criteria were used to include studies:1) study type: observational studies; 2) study period: studies published until 30 November 2023; 3) study area: studies conducted in Ethiopia; 4) Population: people diagnosed with stroke and aged≥18 years; and 5) Published in the English language. Observational studies were included to ensure a focus on real-world data and provide valuable insights into the prevalence of AF among stroke patients in the setting. Case reports, case series, review articles, and letters to editors were excluded. The exclusion of case reports, case series, review articles, and letters to editors helps to maintain the focus on empirical data and avoid potential biases associated with these study types. The CoCoPo format was described as follows:

- Condition (Co): Studies that assessed the prevalence AF among stroke patients.
- Context (Co): studies conducted in Ethiopia.
- Population (Po): studies that were done among adult stroke patients.

Statistical analysis

STATA version 18 Statistical software (Stata Corp, College Station, Texas, USA) was used for the analysis, and heterogeneity was checked across studies by computing the I^2 statistical test. We assumed no, low, medium, and high heterogeneity across studies if the I^2 values were 0%, 25%, 50%, and 75%, respectively. A random effects model was used to analyze the pooled estimated prevalence with 95% confidence intervals (CI) using the "metaprop" command. Funnel plots for visual inspection and Egger's and Begg's rank tests were used to assess the evidence of

publication bias. A forest plot was used to report the estimated pooled prevalence of AF.

Outcome measurement

The study aimed to gather and analyze data from various studies conducted in Ethiopia to determine the pooled prevalence of AF among stroke patients. A systematic approach was employed to identify relevant studies and extract data on outcome measurements, including the prevalence of AF among stroke patients. Statistical methods were then used to combine the data from different studies and estimate the overall prevalence of AF. The critical variables were such as potential risk factors and common medications that serve as prophylaxis to prevent AF not covered in this review. While these variables were not explicitly reported in the primary studies, future research could explore additional factors, such as potential risk factors (e.g., age, hypertension, diabetes, smoking) and the use of common medications (e.g., anticoagulants, beta-blockers) to prevent AF.

Results

Search results

Initially, a total of 105 articles were identified through searches of different databases. Of the identified studies, 41 were removed due to duplication. Thirteen were excluded after reviewing their abstracts and titles. The full texts of the remaining fifty-one articles were sought for retrieval, of which 22 were removed and the remaining (n=29) included full assessment based on the eligibility criteria. We again excluded (n=6) articles, which didn't report the outcome of interest. Finally, the review included 23 studies conducted between 2015 and 2023. Figure 1 illustrates the process of the literature review, screening, and eligibility assessment of the study articles.

Characteristics of the included studies

Of the 21 studies included in the final analysis, eight were from the Amhara region [33-40], and five were from Addis Ababa city [41-45] and the other six were from Oromia region [46-51]. There were three articles each from the Tigray region [52-54]. Only one study was from the South Nations, Nationalities, and Peoples Region (SNNPR) [55]. There were no studies reported from other administrative regions of the country. In terms of study design, ten studies employed a retrospective crosssectional study design [33, 34, 36-38, 42-44, 46, 50, 53], ten were conducted using a prospective cross-sectional design [35, 39-41, 47-49, 52, 54, 55], and one study used a prospective cohort [45] and the other two retrospective cohort design [34, 51] (Table 1).

Table 1 Baseline characteristics of the included studies

Author, publication year	Study design	Region	Facility Name	Mean age (years)	Gender (Female)	Sample size	AF cases (n)
Ameha, 2020 [42]	Retrospective cross-sectional	Oromia	JMC	62:33±15:77	32.7	220	12
Ayalew, 2017 [37]	Prospective cross-sectional	Addis Ababa	TASH	53 ± 17	44	104	7
Ayehu, 2019 [<mark>38</mark>]	Retrospective cross-sectional	Addis Ababa	TASH	52.49±17.53	42.9	170	23
Belayneh, 2019 [<mark>43</mark>]	Prospective cross-sectional	Oromia	AURH	63.36 ± 12.60	50.5	111	22
Beza, 2016 [36]	Prospective cross sectional	Amhara	FHRH	Na	36.8	427	21
Bikila, 2017 [<mark>39</mark>]	Retrospective cross-sectional	Addis Ababa	SPMMC	57.5±15.8	43.6	163	24
Birrie, 2015 [51]	Prospective cross-sectional	SNNPR	HURH	53.1±16.9	33.7	163	12
Ermias, 2015 [29]	Retrospective cross-sectional	Amhara	UGH	68	53.1	98	27
Eyob, 2018 [<mark>30</mark>]	Retrospective cohort	Amhara	UGH	65.17±14.068	57.7	208	76
Firomsa, 2023 [44]	Prospective cross-sectional	Oromia	MKGH, BGH	57.9	37	135	9
Gashaw, 2022 [<mark>3</mark> 1]	Prospective cross-sectional	Amhara	UGH, TGSP, FHRH	61±12.85	53.3	554	5
Ginenus, 2019 [<mark>45</mark>]	Prospective cross sectional	Oromia	JMC	55.1±14.0	37.1	116	19
Hayet, 2018 [46]	Retrospective cross-sectional	Oromia	JMC	Na	32.07	367	45
Henok, 2020 [<mark>32</mark>]	Retrospective cross-sectional	Amhara	DMRH	60	53.7	162	30
Hussein, 2022 [33]	Retrospective cross-sectional	Amhara	DCSH	59.2 ± 14.6	51.9	312	47
Kibreab, 2023 [<mark>48</mark>]	Prospective cross-sectional	Tigray	ACSH	Na	57.4	272	22
Menbeu, 2017 [<mark>40</mark>]	Retrospective cross-sectional	Addis Ababa	TASH	55	57.5	301	43
Samson, 2018 [34]	Retrospective cross-sectional	Amhara	FHRH	Na	37	508	37
Seid, 2019 [<mark>35</mark>]	Prospective cross-sectional	Amhara	UGH	65	50.3	151	33
Sennay, 2023 [<mark>49</mark>]	Retrospective cross-sectional	Tigray	ACSH	62.8±15.6	45.8	142	11
Solomon, 2020 [50]	Prospective cross-sectional	Tigray	ACSH	61.2±15.6	58.3	216	21
Wakgari, 2023 [47]	Retrospective cohort	Oromia	JMC	55.43±14.56	37.71	480	146
Yared, 2015 [41]	Prospective cohort	Addis Ababa	TASH, BTH, ZMH	52.7±17.6	39	71	4

ACSH: Ayder Comprehensive Specialized Hospital; AURH: Ambo University Referral Hospital; DCSH: Dessie Comprehensive Specialized Hospital; SPMMC : St. Paul's Millennium Medical College; HURH: Hawassa University Referral Hospital; UGH: University of Gondar Hospital; TGSP: Tibebe Ghion Specialized Hospital; FHRH: Felege Hiwot Referral Hospital; DMRH: Debre Markos Referral Hospital; MKGH: Mettu Karl General Hospital; BGH: Bedele General Hospital; BTH: Bethel Teaching Hospital; ZMH: Zewditu Memorial Hospital; SNNPR: South Nations, Nationalities and Peoples Region

Pooled prevalence estimates of AF

A total of 5451 stroke patients were assessed in the included studies; 696 of them were diagnosed with AF, yielding a pooled prevalence of 13% [95% CI: (10%, 17%)] among stroke patients in Ethiopia (Fig. 2).

Subgroup analysis

We conducted a subgroup analysis of the prevalence of AF among stroke patients based on different variables (i.e., region, year of publication, and study design). The subgroup analysis by region revealed that the highest pooled prevalence of AF was 16% [95% CI: (8 -25%)], which was from the Amhara region, which was followed by Oromia region 15% % [95% CI: (7 -23%)]. Addis Ababa city had pooled prevalence 11% [95% CI: (7 -15%)] of AF among stroke patients, respectively. The pooled prevalence of AF among stroke patients in the Tigray region was 9% [95% CI: (6 -11%)]. However, one study reported the prevalence of AF among stroke patients from South, nations, nationalities, and people's region, which was 7% [95% CI: (3 -11%)] (Fig. 3).

The other subgroup analysis was performed based on the study design, which showed the pooled prevalence of

AF among stroke patients 10% [95% CI: (6%, 14%)] and 13% [95% CI: (9%,16%)] for prospective cross-sectional and retrospective cross-sectional studies, respectively. However, three cohort studies (two retrospective and one prospective) reported a pooled prevalence of 33% [95% CI: (27%, 39%)] and 6% [95% CI: (0%,11%)] (Fig. 4). In general, Fig. 5 shows the pooled prevalence of AF 9% [95% CI: (6%, 13%)] from the prospective study and 17% [95% CI: (11%, 22%)] from the retrospective study. Moreover, we have conducted a subgroup analysis based on the year of publication as between 2015 and 2020 and studies published in 2020 and later. The pooled prevalence of AF among stroke patients from studies published in 2020 and later was 11% [95% CI: (5%, 17%)] and from those published between 2015 and 2020 was 15% [95% CI: (10%, 19%)] (Fig. 6).

Publication bias

Funnel plots (visual inspection) and Egger and Begg rank statistical tests at the 5% significance level were used to assess the presence of publication bias. Although, the funnel plot showed asymmetry (Fig. 7) for pooled estimates of AF, and the Egger and Begg rank test didn't

Study	Number of successes	Total						Prevalence with 95% Cl	Weight (%)
Ameha, 2020	12	220						0.05 [0.02, 0.08]	4.38
Ayalew, 2017	7	104						0.07 [0.02, 0.12]	4.16
Ayehu, 2019	23	170						0.14 [0.08, 0.19]	4.11
Belayneh, 2019	22	111						0.20 [0.12, 0.27]	3.73
Beza, 2016	21	427		-				0.05 [0.03, 0.07]	4.46
Bikila, 2017	24	163						0.15 [0.09, 0.20]	4.06
Birrie, 2015	12	163						0.07 [0.03, 0.11]	4.26
Ermias, 2015	27	98				_	_	0.28 [0.19, 0.36]	3.48
Eyob, 2018	76	208						- 0.37 [0.30, 0.43]	3.89
Firomsa, 2023	9	135						0.07 [0.02, 0.11]	4.24
Gashaw, 2022	5	554						0.01 [0.00, 0.02]	4.52
Ginenus, 2019	19	116			-			0.16 [0.10, 0.23]	3.85
Hayet, 2018	45	367		-	-			0.12 [0.09, 0.16]	4.34
Henok, 2020	30	162				_		0.19 [0.13, 0.25]	3.98
Hussen, 2022	47	312		-				0.15 [0.11, 0.19]	4.27
Kibreab, 2023	22	272						0.08 [0.05, 0.11]	4.35
Menbeu, 2017	43	301			-			0.14 [0.10, 0.18]	4.27
Samson, 2018	37	508						0.07 [0.05, 0.10]	4.44
Seid, 2019	33	151				<u> </u>		0.22 [0.15, 0.28]	3.88
Sennay, 2023	11	142						0.08 [0.03, 0.12]	4.21
Solomon, 2020	21	216			_			0.10 [0.06, 0.14]	4.27
Wakgari, 2023	146	480						0.30 [0.26, 0.35]	4.25
Yared, 2015	4	71		——				0.06 [0.00, 0.11]	4.08
	696	5,451						0.13 [0.12, 0.14]	4.52
Overall								0.13 [0.10, 0.17]	
Heterogeneity: T ²	$r^2 = 0.01, I^2 = 9$	97.37%, H ⁱ	² = 37.96						
Test of $\theta_i = \theta_j$: Q(23) = 723.36	, p = 0.00							
Test of $\theta = 0$: z =	7.55, p = 0.0	0							
				0.1	.2	.3	.4	-	
Random-effects R	EML model								

Fig. 2 Forest plot depicting the overall pooled prevalence estimate of AF among stroke patients in Ethiopia

showed evidence of statistically significant publication bias (p=0.132 and P- value=0.273) respectively.

Sensitivity analysis

By excluding each study individually, a leave-out-one sensitivity analysis was used to determine the effect of a single study on the pooled prevalence of AF among stroke patients in Ethiopia. According to our findings, no single study had a significant impact on the pooled prevalence of AF among stroke patients in Ethiopia (Fig. 8).

Discussion

The current systematic review and meta-analysis conducted in Ethiopia found a pooled prevalence of atrial fibrillation (AF) among stroke patients to be 13% (95% CI: 10%, 17%). A study by Wolf et al. [56] also found that AF is a significant risk factor for stroke, with a prevalence of about 15% among stroke patients. This aligns closely with the current overall pooled prevalence. Similar studies have been conducted in other geographic regions to investigate the prevalence of AF among stroke patients. For instance, a systematic review by Wang et al. [57] estimated the overall prevalence of AF in patients with acute ischemic stroke to be 17.7%. This figure is slightly higher than the Ethiopian findings, potentially due to differences in sample size, study settings, and detection capabilities. A meta-analysis by Kamel et al. [58] found that a prevalence of AF 16.1%. This figure was slightly higher than the prevalence observed in our study. The discrepancy might be attributed to the larger number of studies included in Kamel et al.'s meta-analysis.

Moreover, the prevalence of AF exhibited significant regional disparities, ranging from 7 to 16%. The findings highlight the notable burden of AF in this population, particularly in the Amhara (16%) and Oromia (15%) regions. A single study from the Southern nations,

Study	Number of successes		Prevalence with 95% Cl	Weig (%)
Addis Ababa				
Ayalew, 2017	7	104	0.07 [0.02, 0.12]	4.16
Ayehu, 2019	23	170	0.14 [0.08, 0.19]	4.11
Bikila, 2017	24	163	0.15 [0.09, 0.20]	4.06
Menbeu, 2017	43	301		4.27
Yared, 2015	4	71	0.06 [0.00, 0.11]	4.08
Heterogeneity: T ²	= 0.00, I ² =	67.35%, H ² = 3.06	0.11 [0.07, 0.15]	
Test of $\theta_i = \theta_j$: Q(4)) = 12.18, p	0 = 0.02		
Test of $\theta = 0$: z =	5.65, p = 0.	00		
Amhara				
Beza, 2016	21	427	0.05 [0.03, 0.07]	4.46
Ermias, 2015	27	98	0.28 [0.19, 0.36]	3.48
Eyob, 2018	76	208	0.37 [0.30, 0.43]	3.89
Gashaw, 2022	5	554	0.01 [0.00, 0.02]	4.52
Henok, 2020	30	162	0.19 [0.13, 0.25]	3.98
Hussen, 2022	47	312	0.15 [0.11, 0.19]	4.27
Samson, 2018	37	508	0.07 [0.05, 0.10]	4.44
Seid, 2019	33	151	0.22 [0.15, 0.28]	3.88
Heterogeneity: T ²	= 0.01, I ² =	98.66%, H ² = 74.48	0.16 [0.08, 0.25]	
Test of $\theta_i = \theta_j$: Q(7)) = 266.96,	p = 0.00		
Test of $\theta = 0$: $z = 1$	3.79, p = 0.	00		
Oromia				
Ameha, 2020	12	220		4.38
Belayneh, 2019	22	111	0.20 [0.12, 0.27]	3.73
Firomsa, 2023	9	135	0.07 [0.02, 0.11]	4.24
Ginenus, 2019	19	116	0.16 [0.10, 0.23]	3.85
Hayet, 2018	45	367		4.34
Wakgari, 2023	146	480	0.30 [0.26, 0.35]	4.25
Heterogeneity: T ²	= 0.01, I ² =	94.70%, H ² = 18.88	0.15 [0.07, 0.23]	
Test of $\theta_i = \theta_j$: Q(5)	5) = 106.17,	p = 0.00		
Test of $\theta = 0$: z =	3.87, p = 0.	00		
SNNPR				
Birrie, 2015	12	163	0.07 [0.03, 0.11]	4.26
Heterogeneity: τ ²	= 0.00, I ² =	.%, H ² = .	0.07 [0.03, 0.11]	
Test of $\theta_i = \theta_j$: Q(0)) = -0.00, p	= .		
Test of $\theta = 0$: $z = 2$	3.60, p = 0.	00		
Tigray				
Kibreab, 2023	22	272	0.08 [0.05, 0.11]	4.3
Sennay, 2023	11	142	0.08 [0.03, 0.12]	4.2
Solomon, 2020	21	216	0.10 [0.06, 0.14]	4.27
		0.01%, H ² = 1.00	0.09 [0.06, 0.11]	
• •				
Heterogeneity: τ^2 Test of $\theta_i = \theta_j$: Q(2		00		
• •	7.65, p = 0.			
Test of $\theta_i = \theta_j$: Q(2)	7.65, p = 0.		0.13 [0.10, 0.17]	
Test of $\theta_i = \theta_j$: Q(2 Test of $\theta = 0$: z = Overall		96.35%, H ² = 27.37	0.13 [0.10, 0.17]	
Test of $\theta_i = \theta_j$: Q(2 Test of $\theta = 0$: z = Overall	= 0.01, I ² =		0.13 [0.10, 0.17]	
Test of $\theta_i = \theta_j$: Q(2 Test of $\theta = 0$: z = Overall Heterogeneity: τ^2	= 0.01, I ² = 22) = 537.35	5, p = 0.00	0.13 [0.10, 0.17]	

Fig. 3 Forest plot depicting the subgroup analysis of pooled prevalence estimate of AF among stroke patients based on region in Ethiopia

nationalities, and people's region reported a prevalence of 7%. Such regional (geographical) variation has been reported in other studies too [59-61]. Geographic differences in AF prevalence can often be linked to varying

risk factors, such as hypertension and diabetes, which are known to be more prevalent in certain areas [62]. For example, the prevalence of risk factors for AF such as hypertension, diabetes, and obesity may vary between

Study	Number of successes	Total	Prevalence with 95% CI	Weigh (%)
Prospective cohort				
Yared, 2015	4	71	0.06 [0.00, 0.11]	4.08
Heterogeneity: $\tau^2 = 0.00$, $I^2 = .$.%, H ² = .		0.06 [0.00, 0.11]	
Test of $\theta_i = \theta_j$: Q(0) = 0.00, p =	=.		•	
Test of θ = 0: z = 2.06, p = 0.0)4			
Prospective cross sectional	ł			
Ayalew, 2017	7	104	0.07 [0.02, 0.12]	4.16
Belayneh, 2019	22	111	0.20 [0.12, 0.27]	3.73
Beza, 2016	21	427	0.05 [0.03, 0.07]	4.46
Birrie, 2015	12	163	0.07 [0.03, 0.11]	4.26
Firomsa, 2023	9	135	0.07 [0.02, 0.11]	4.24
Gashaw, 2022	5	554	0.01 [0.00, 0.02]	4.52
Ginenus, 2019	19	116	0.16 [0.10, 0.23]	3.85
Kibreab, 2023	22	272		4.35
Seid, 2019	33	151		3.88
Solomon, 2020	21	216		4.27
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 9$			0.10 [0.06, 0.14]	
Test of $\theta_i = \theta_i$: Q(9) = 127.13,		50		
Test of $\theta = 0$: z = 4.71, p = 0.0				
Retrospective cohort				
-	76	208	0.2710.20.0421	2 90
Eyob, 2018	76 146			3.89
Wakgari, 2023 Heterogeneity: τ ² = 0.00, Ι ² = {		480		4.25
Test of $\theta_i = \theta_i$: Q(1) = 2.41, p =		1	0.33 [0.27, 0.39]	
Test of $\theta = 0$: z = 10.94, p = 0				
Retrospective cross-sectior	nal			
Ameha, 2020	12	220	0.05 [0.02, 0.08]	4.38
Ayehu, 2019	23	170	0.14 [0.08, 0.19]	4.11
Bikila, 2017	24	163	0.15 [0.09, 0.20]	4.06
Ermias, 2015	27	98	0.28 [0.19, 0.36]	3.48
Hayet, 2018	45	367		4.34
Henok, 2020	30	162		
				3.98
Hussen, 2022	47	312		4.27
Menbeu, 2017	43	301		4.27
Samson, 2018	37	508		4.44
Conney 2022	11	142	0.08 [0.03, 0.12]	4.21
Sennay, 2023 Heterogeneity: x ² = 0.00, J ² = 1	$26 100 / 11^2 - 7 47$	n	0.1310.09. 0.16	
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 8$		9	• • • • • • • • • • • • • • • •	
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 8$ Test of $\theta_i = \theta_j$: Q(9) = 54.62, p	= 0.00	9	•	
Heterogeneity: $\tau^2 = 0.00$, $I^2 = 8$ Test of $\theta_i = \theta_j$: Q(9) = 54.62, p	= 0.00	Э	•	
Heterogeneity: $\tau^2 = 0.00$, $l^2 = 4$ Test of $\theta_i = \theta_j$: Q(9) = 54.62, p Test of $\theta = 0$: z = 7.37, p = 0.0 Overall	= 0.00 00		0.13 [0.10, 0.17]	
Heterogeneity: $\tau^2 = 0.00$, $l^2 = 4$ Test of $\theta_i = \theta_j$: Q(9) = 54.62, p Test of $\theta = 0$: z = 7.37, p = 0.0 Overall Heterogeneity: $\tau^2 = 0.01$, $l^2 = 4$	= 0.00)0 96.35%, H ² = 27.3			
Heterogeneity: $\tau^2 = 0.00$, $l^2 = 4$ Test of $\theta_i = \theta_j$: Q(9) = 54.62, p Test of $\theta = 0$: z = 7.37, p = 0.0 Overall Heterogeneity: $\tau^2 = 0.01$, $l^2 = 4$	= 0.00)0 96.35%, H ² = 27.3			
Heterogeneity: $\tau^2 = 0.00$, $l^2 = 4$ Test of $\theta_i = \theta_j$: Q(9) = 54.62, p Test of $\theta = 0$: z = 7.37, p = 0.0 Overall	= 0.00 00 96.35%, H ² = 27.3 , p = 0.00			

Fig. 4 Forest plot depicting the subgroup analysis of pooled prevalence estimate of AF among stroke patients based on study design in Ethiopia

regions, which could contribute to differences in AF prevalence among stroke patients [62]. Additionally, access to healthcare and diagnostic resources may also differ between regions, potentially impacting the detection and reporting of AF cases [6, 63]. The observed variations in AF prevalence across regions highlight the importance of considering geographic factors when studying stroke epidemiology and risk stratification. Further research

Prospective study Ayalew, 2017 Belayneh, 2019 Beza, 2016 Birrie, 2015 Firomsa, 2023 Gashaw, 2022 Ginenus, 2019 Kibreab, 2023 Seid, 2019 Solomon, 2020 Yared, 2015 Heterogeneity: $r^2 = 0.00$, l^2 Test of θ _i = θ _j : Q(10) = 128. Test of θ = 0: z = 4.94, p = 10000000000000000000000000000000000	7 22 21 12 9 5	Total 104 111 427 163	with 95% CI 0.07 [0.02, 0.12] 0.20 [0.12, 0.27] 0.05 [0.03, 0.07]	(%) 4.16 3.73
Ayalew, 2017 Belayneh, 2019 Beza, 2016 Birrie, 2015 Firomsa, 2023 Gashaw, 2022 Ginenus, 2019 Kibreab, 2023 Seid, 2019 Solomon, 2020 Yared, 2015 Heterogeneity: $\tau^2 = 0.00$, I^2 Test of $\theta_i = \theta_j$: Q(10) = 128. Test of $\theta = 0$: $z = 4.94$, $p = 1$ Retrospective study Ameha, 2020 Ayehu, 2019 Bikila, 2017 Ermias, 2015	22 21 12 9	111 427	0.20 [0.12, 0.27]	3.73
Belayneh, 2019 Beza, 2016 Birrie, 2015 Firomsa, 2023 Gashaw, 2022 Ginenus, 2019 Kibreab, 2023 Seid, 2019 Solomon, 2020 Yared, 2015 Heterogeneity: $r^2 = 0.00$, l^2 Test of $\theta_i = \theta_j$: Q(10) = 128. Test of $\theta = 0$: $z = 4.94$, $p = 100$ Retrospective study Ameha, 2020 Ayehu, 2019 Bikila, 2017 Ermias, 2015	22 21 12 9	111 427	0.20 [0.12, 0.27]	3.73
Beza, 2016 Birrie, 2015 Firomsa, 2023 Gashaw, 2022 Ginenus, 2019 Kibreab, 2023 Seid, 2019 Solomon, 2020 Yared, 2015 Heterogeneity: $r^2 = 0.00$, l^2 Test of $\theta_i = \theta_j$: Q(10) = 128. Test of $\theta = 0$: $z = 4.94$, $p = 100$ Retrospective study Ameha, 2020 Ayehu, 2019 Bikila, 2017 Ermias, 2015	21 12 9	427		
Birrie, 2015 Firomsa, 2023 Gashaw, 2022 Ginenus, 2019 Kibreab, 2023 Seid, 2019 Solomon, 2020 Yared, 2015 Heterogeneity: $\tau^2 = 0.00$, I^2 Test of $\theta_i = \theta_j$: Q(10) = 128. Test of $\theta = 0$: $z = 4.94$, $p = 100$ Retrospective study Ameha, 2020 Ayehu, 2019 Bikila, 2017 Ermias, 2015	12 9			4 4 0
Firomsa, 2023 Gashaw, 2022 Ginenus, 2019 Kibreab, 2023 Seid, 2019 Solomon, 2020 Yared, 2015 Heterogeneity: $r^2 = 0.00$, l^2 Test of $\theta_i = \theta_j$: Q(10) = 128. Test of $\theta = 0$: $z = 4.94$, $p = 100$ Retrospective study Ameha, 2020 Ayehu, 2019 Bikila, 2017 Ermias, 2015	9	163		4.46
Gashaw, 2022 Ginenus, 2019 Kibreab, 2023 Seid, 2019 Solomon, 2020 Yared, 2015 Heterogeneity: $r^2 = 0.00$, l^2 Test of $\theta_i = \theta_j$: Q(10) = 128. Test of $\theta = 0$: $z = 4.94$, $p = 100$ Retrospective study Ameha, 2020 Ayehu, 2019 Bikila, 2017 Ermias, 2015			0.07 [0.03, 0.11]	4.26
Ginenus, 2019 Kibreab, 2023 Seid, 2019 Solomon, 2020 Yared, 2015 Heterogeneity: $\tau^2 = 0.00$, I^2 Test of $\theta_i = \theta_j$: Q(10) = 128. Test of $\theta = 0$: $z = 4.94$, $p = 100$ Retrospective study Ameha, 2020 Ayehu, 2019 Bikila, 2017 Ermias, 2015	5	135	0.07 [0.02, 0.11]	4.24
Kibreab, 2023 Seid, 2019 Solomon, 2020 Yared, 2015 Heterogeneity: $r^2 = 0.00$, l^2 Test of $\theta_i = \theta_j$: Q(10) = 128. Test of $\theta = 0$: $z = 4.94$, $p = 100$ Retrospective study Ameha, 2020 Ayehu, 2019 Bikila, 2017 Ermias, 2015		554	0.01 [0.00, 0.02]	4.52
Seid, 2019 Solomon, 2020 Yared, 2015 Heterogeneity: $\tau^2 = 0.00$, I^2 Test of $\theta_i = \theta_j$: Q(10) = 128. Test of $\theta = 0$: $z = 4.94$, $p = 100$ Retrospective study Ameha, 2020 Ayehu, 2019 Bikila, 2017 Ermias, 2015	19	116	0.16 [0.10, 0.23]	3.85
Solomon, 2020 Yared, 2015 Heterogeneity: $\tau^2 = 0.00$, I^2 Test of $\theta_i = \theta_j$: Q(10) = 128. Test of $\theta = 0$: $z = 4.94$, $p = 100$ Retrospective study Ameha, 2020 Ayehu, 2019 Bikila, 2017 Ermias, 2015	22	272	0.08 [0.05, 0.11]	4.35
Yared, 2015 Heterogeneity: $r^2 = 0.00$, l^2 Test of $\theta_i = \theta_j$: Q(10) = 128. Test of $\theta = 0$: z = 4.94, p = l^2 Retrospective study Ameha, 2020 Ayehu, 2019 Bikila, 2017 Ermias, 2015	33	151		3.88
Heterogeneity: $\tau^2 = 0.00$, I^2 Test of $\theta_i = \theta_i$: Q(10) = 128. Test of $\theta = 0$: $z = 4.94$, $p = 100$ Retrospective study Ameha, 2020 Ayehu, 2019 Bikila, 2017 Ermias, 2015	21	216		4.27
Test of $\theta_i = \theta_j$: Q(10) = 128. Test of $\theta = 0$: z = 4.94, p = Retrospective study Ameha, 2020 Ayehu, 2019 Bikila, 2017 Ermias, 2015	4	71	0.06 [0.00, 0.11]	4.08
Test of θ = 0: z = 4.94, p = Retrospective study Ameha, 2020 Ayehu, 2019 Bikila, 2017 Ermias, 2015	= 93.17%	%, H ² = 14.65	0.09 [0.06, 0.13]	
Retrospective study Ameha, 2020 Ayehu, 2019 Bikila, 2017 Ermias, 2015	15, p = 0	.00		
Ameha, 2020 Ayehu, 2019 Bikila, 2017 Ermias, 2015	0.00			
Ayehu, 2019 Bikila, 2017 Ermias, 2015				
Bikila, 2017 Ermias, 2015	12	220		4.38
Ermias, 2015	23	170	0.14 [0.08, 0.19]	4.11
	24	163	0.15 [0.09, 0.20]	4.06
	27	98	0.28 [0.19, 0.36]	3.48
Eyob, 2018	76	208		3.89
Hayet, 2018	45	367		4.34
Henok, 2020	30	162	0.19 [0.13, 0.25]	3.98
Hussen, 2022	47	312	0.15 [0.11, 0.19]	4.27
Menbeu, 2017	43	301	0.14 [0.10, 0.18]	4.27
Samson, 2018	37	508		4.44
Sennay, 2023	11	142	0.08 [0.03, 0.12]	4.21
Wakgari, 2023	146	480		4.25
Heterogeneity: $\tau^2 = 0.01$, I^2	= 95.22%	$%, H^2 = 20.94$	0.17 [0.11, 0.22]	
Test of $\theta_i = \theta_j$: Q(11) = 188.				
Test of θ = 0: z = 6.02, p =				
Overall			0.13 [0.10, 0.17]	
Heterogeneity: $\tau^2 = 0.01$, I^2	= 96 350	$4 H^2 = 27.27$		
Test of $\theta_i = \theta_i$: Q(22) = 537.				
Test of $\theta_i = \theta_j$: Q(22) = 537. Test of $\theta = 0$: z = 7.21, p =		.00		
Test of aroun difforences: (). (1) – <i>4</i>	95 n = 0.02		
Test of group differences: C	×ь(1) − 4.	əə, p – 0.03	0 .1 .2 .3 .4	

Fig. 5 Forest plot depicting the subgroup analysis of pooled prevalence estimate of AF among stroke patients based on study design in Ethiopia

	Number of					Prevalence	Weight
Study	successes	Total	1			with 95% CI	(%)
2020 and later							
Ameha, 2020	12	220				0.05 [0.02, 0.08]	4.38
Firomsa, 2023	9	135				0.07 [0.02, 0.11]	4.24
Gashaw, 2022	5	554				0.01 [0.00, 0.02]	4.52
Henok, 2020	30	162		_		0.19 [0.13, 0.25]	3.98
Hussen, 2022	47	312		-		0.15 [0.11, 0.19]	4.27
Kibreab, 2023	22	272				0.08 [0.05, 0.11]	4.35
Sennay, 2023	11	142				0.08 [0.03, 0.12]	4.21
Solomon, 2020	21	216				0.10 [0.06, 0.14]	4.27
Wakgari, 2023	146	480		-	-	0.30 [0.26, 0.35]	4.25
Heterogeneity: $\tau^2 = 0.01$,	² = 96.99%, H ²	= 33.26				0.11 [0.05, 0.17]	
Test of $\theta_i = \theta_j$: Q(8) = 287.	55, p = 0.00						
Test of θ = 0: z = 3.83, p =	= 0.00						
Between 2015 and 2020							
Ayalew, 2017	7	104				0.07 [0.02, 0.12]	4.16
Ayehu, 2019	23	170				0.14 [0.08, 0.19]	4.11
Belayneh, 2019	22	111		_		0.20 [0.12, 0.27]	3.73
Beza, 2016	21	427	-			0.05 [0.03, 0.07]	4.46
Bikila, 2017	24	163		-		0.15 [0.09, 0.20]	4.06
Birrie, 2015	12	163				0.07 [0.03, 0.11]	4.26
Ermias, 2015	27	98				0.28 [0.19, 0.36]	3.48
Eyob, 2018	76	208				- 0.37 [0.30, 0.43]	3.89
Ginenus, 2019	19	116	— I			0.16 [0.10, 0.23]	3.85
Hayet, 2018	45	367				0.12 [0.09, 0.16]	4.34
Menbeu, 2017	43	301	-			0.14 [0.10, 0.18]	4.27
Samson, 2018	37	508	-			0.07 [0.05, 0.10]	4.44
Seid, 2019	33	151			-	0.22 [0.15, 0.28]	3.88
Yared, 2015	4	71				0.06 [0.00, 0.11]	4.08
Heterogeneity: $\tau^2 = 0.01$,	² = 94.14%, H ²	= 17.06				0.15 [0.10, 0.19]	
Test of $\theta_i = \theta_j$: Q(13) = 146	6.99, p = 0.00						
Test of θ = 0: z = 6.12, p =	= 0.00						
Overall						0.13 [0.10, 0.17]	
Heterogeneity: $\tau^2 = 0.01$,	² = 96.35%, H ²	= 27.37					
Test of $\theta_i = \theta_j$: Q(22) = 53	7.35, p = 0.00						
Test of θ = 0: z = 7.21, p =	= 0.00						
Test of group differences:	$O_{1}(1) = 0.74$ r	n = 0.39					
lest of group differences.	$\sim v(r) = 0.1 + 1$. 0.00		0	2 4	_	
			0.1	.2	.3 .4		

Fig. 6 Forest plot depicting the subgroup analysis of pooled prevalence estimate of AF among stroke patients based on year of publication in Ethiopia

is needed to elucidate the underlying causes of these regional differences and to develop targeted prevention strategies.

The prevalence of AF among stroke patients higher in retrospective studies (17%) compared to prospective studies (9%). The findings align with previous literature that indicates variability in AF prevalence based on study design. For example, a meta-analysis by Lip et al. [8] reported similar trends, emphasizing how study methodologies can influence observed outcomes. Furthermore, a study by Desteghe et al. [64, 65] highlighted the importance of study design in prevalence estimation,




Fig. 7 The funnel plot shows publication bias




Fig. 8 Sensitivity analysis for single study effect of estimated pooled prevalence of AF among stroke patients

suggesting that prospective studies may provide more reliable estimates due to their structured data collection methods. The higher prevalence rates observed in retrospective studies might be influenced by biases inherent in retrospective data collection, such as selective reporting or incomplete data. The subgroup analysis reveals a notable difference in the pooled prevalence of AF among stroke patients based on the publication year. Studies published in 2020 and later reported a lower prevalence (11%) compared to those published between 2015 and 2020 (15%). Some studies published after 2020 [23, 66] have reported similar declines in AF prevalence, attributing these changes to better awareness and treatment of risk factors. Enhanced stroke prevention strategies and the management of cardiovascular risk factors (e.g., hypertension, diabetes) in recent years might have contributed to a lower rate of AF in stroke patients. However, not all studies agree. Some have reported stable or even increasing rates of AF [67, 68], particularly in older populations, highlighting the variability based on geographic and demographic factors.

These findings highlight the critical need for healthcare interventions focused on the management of AF among stroke patients in Ethiopia. Addressing this issue through targeted public health initiatives and increasing awareness among healthcare providers can significantly improve patient outcomes and reduce the burden of stroke in this population. Future research should focus on understanding the underlying factors contributing to the observed regional variations and developing tailored strategies to enhance AF management in Ethiopia.

Strength and limitations

This systematic review and meta-analysis have several strengths. It was the first review that dealt with the pooled prevalence of AF among high-risk patients (i.e., stroke) for poor prognosis. Unlike the previous study [69], the current review included 23 research articles, which provides a comprehensive overview of the prevalence of AF among stroke patients in Ethiopia. The subgroup analysis by region provides a more nuanced understanding of the regional disparities in atrial fibrillation (AF) prevalence among stroke patients. This information can inform targeted interventions and healthcare resource allocation. It is anticipated to contribute significantly to a comprehensive understanding of AF prevalence in this patient population. Future research should focus on addressing the remaining gaps in the literature to enhance clinical management and public health interventions for stroke patients with AF.

However, it is important to acknowledge the limitations of this analysis. The findings may be specific to the Ethiopian context and may not be generalizable to other populations or settings. Moreover, the retrospective nature of the included studies introduces inherent biases. Patients in retrospective studies may not represent the general population, potentially leading to skewed results. Additionally, data collected retrospectively may rely on patient recall or incomplete medical records, affecting accuracy.

Despite the valuable insights provided by these systematic reviews and meta-analyses, there are still inconsistencies and gaps in the literature that require further investigation. For example, the underlying factors contributing to regional variations in AF prevalence among stroke patients remain unclear and necessitate additional research. Furthermore, more studies are needed to explore the impact of specific risk factors or comorbidities on AF prevalence in this population.

Conclusion

In conclusion, the prevalence of AF among stroke patients in Ethiopia was found to be 13%, with regional variations ranging from 7 to 16%. These findings highlight the importance of considering demographic and healthcare differences between regions when assessing the prevalence of AF among stroke patients. The high prevalence of AF underscores the need for effective strategies to identify and manage this condition to prevent recurrent strokes. Targeted interventions, such as anticoagulation therapy, may be warranted for stroke patients with AF to reduce their risk of future cardiovascular events.

Abbreviations

AF	atrial fibrillation
CI	Confidence Interval
PRISMA	Preferred Reporting Items for Systematic Reviews and
	Meta-Analyses
MOOSE	Meta-analysis of Observational Studies in Epidemiology guideline
ACSH	Ayder Comprehensive Specialized Hospital
AURH	Ambo University Referral Hospital
DCSH	Dessie Comprehensive Specialized Hospital
SPMMC	St. Paul's Millennium Medical College
HURH	Hawassa University Referral Hospital
UGH	University of Gondar hospital
TGSP	Tibebe Ghion Specialized Hospital
FHRH	Felege Hiwot Referral Hospital
DMRH	Debre Markos Referral Hospital
MKGH	Mettu Karl General Hospital
BGH	Bedele General Hospital
BTH	Bethel Teaching Hospital
ZMH	Zewditu Memorial Hospital
SNNPR	South Nations, Nationalities and Peoples Region

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12883-024-03894-8.

Supplementary Material 2	
Supplementally material 2	
Supplementary Material 3	,

Acknowledgements

We are indebted to all the researchers whose studies were included in this study.

Author contributions

MM, YS, and TM conducted database search, screening, and quality assessment. MM, YS and TM made substantial contributions to the conception and design, analysis, and interpretation of data; took part in drafting the article, revising it critically; agreed to submit to the current journal; gave final approval of the version to be published; and agreed to be accountable for all aspects of the work. All the authors have read and agreed on the final manuscript.

Funding

This study did not receive any specific grant from any organization in either the public or commercial sector.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Department of Internal Medicine, Institute of Health, Jimma University, Jimma, Ethiopia

²Department of Epidemiology, Wolaita Sodo University, Wolaita Sodo, Ethiopia

³School of Pharmacy, Institute of Health, Jimma University, Jimma, Ethiopia

Received: 9 December 2023 / Accepted: 2 October 2024 Published online: 14 October 2024

References

- Fu D-g. Cardiac arrhythmias: diagnosis, symptoms, and treatments. Cell Biochem Biophys. 2015;73(2):291–6.
- Everett TH, Olgin JE. Basic mechanisms of atrial fibrillation. Cardiol Clin. 2004;22(1):9–20.
- Markides V, Schilling RJ. Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment. Heart. 2003;89(8):939–43.
- Oladiran O, Nwosu I. Stroke risk stratification in atrial fibrillation: a review of common risk factors. J Community Hosp Intern Med Perspect. 2019;9(2):113–20.
- Bencivenga L, et al. Atrial fibrillation in the elderly: a risk factor beyond stroke. Ageing Res Rev. 2020;61:101092.
- Dai H, et al. Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990–2017: results from the global burden of Disease Study 2017. Eur Heart Journal-Quality Care Clin Outcomes. 2021;7(6):574–82.
- Boriani G, et al. Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes. Cardiovascular Res. 2021;117(7):1–21.
- Choi SE, et al. Atrial fibrillation and stroke. Expert Rev Cardiovasc Ther. 2023;21(1):35–56.
- Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217–21.
- Marini C, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36(6):1115–9.
- Ahmad Y, Lip GY, Lane DA. Recent developments in understanding epidemiology and risk determinants of atrial fibrillation as a cause of stroke. Can J Cardiol. 2013;29(7):S4–13.
- 12. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Reviews Cardiol. 2014;11(11):639–54.
- Boriani G, Pettorelli D. Atrial fibrillation burden and atrial fibrillation type: clinical significance and impact on the risk of stroke and decision making for long-term anticoagulation. Vascul Pharmacol. 2016;83:26–35.
- 14. Botto GL, et al. Impact of the pattern of atrial fibrillation on stroke risk and mortality. Arrhythmia Electrophysiol Rev. 2021;10(2):68.
- 15. Luengo-Fernandez R, et al. Population-based study of acute-and long-term care costs after stroke in patients with AF. Int J Stroke. 2013;8(5):308–14.
- Li X, et al. The impact of ischaemic stroke on atrial fibrillation-related healthcare cost: a systematic review. EP Europace. 2017;19(6):937–47.
- Andrew NE, Thrift AG, Cadilhac DA. The prevalence, impact and economic implications of atrial fibrillation in stroke: what progress has been made? Neuroepidemiology. 2013;40(4):227–39.

- Kasmeridis C, et al. Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants. PharmacoEconomics. 2013;31:971–80.
- 19. Andreotti F et al. POLICY RECOMMENDATIONS.
- 20. Olusola O et al. Editorial Consultants Editor's Office. J Trop Med, 2014. 14(2).
- 21. Gallagher C, et al. Integrated care in atrial fibrillation: a systematic review and meta-analysis. Heart. 2017;103(24):1947–53.
- 22. Freedman B et al. World Heart Federation roadmap on atrial fibrillation–a 2020 update. Global Heart, 2021. 16(1).
- Pitman BM, et al. Prevalence and risk factors for atrial fibrillation in a semirural sub-saharan African population: the hEart oF Ethiopia: focus on Atrial Fibrillation (TEFF-AF) Study. Heart Rhythm. 2022;O2(6):839–46.
- 24. Mohsin M et al. The synergistic relationship between Atrial Fibrillation and Diabetes Mellitus: implications for Cardiovascular and Metabolic Health. Cureus, 2023. 15(9).
- 25. Hewage S et al. Global and regional burden of ischemic stroke associated with atrial fibrillation, 2009–2019. Preventive Medicine, 2023: p. 107584.
- 26. Rangnekar G. The characterisation of risk factors, substrate and management strategies for atrial fibrillation. 2015.
- 27. Hassanabad MF et al. Atrial fibrillation and lifestyle: a Comprehensive Review of Major contributing factors. J Atr Fibrillation Electrophysiol, 2022. 15(4).
- Cimmino G, et al. Non-conventional risk factors: fact or fake in cardiovascular disease prevention? Biomedicines. 2023;11(9):2353.
- 29. Kadhim KI. Sleep-Disordered Breathing and Atrial Fibrillation: Prevalence, Detection and Mechanistic Insights. 2022.
- Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.
- Stroup DF, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283(15):2008–12.
- 32. Modesti PA, et al. Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis. PLoS ONE. 2016;11(1):e0147601.
- Greffie ES, Mitiku T, Getahun S. Risk factors, clinical pattern and outcome of stroke in a referral hospital, Northwest Ethiopia. Clin Med Res. 2015;4(6):182–8.
- 34. Gebreyohannes EA et al. *In-hospital mortality among ischemic stroke patients in Gondar University Hospital: a retrospective cohort study.* Stroke research and treatment, 2019. 2019.
- Ayehu GW, et al. Risk profile, clinical presentation, and determinants of stroke subtypes among patients with stroke admitted to public referral hospitals, Northwest Ethiopia in 2021: a cross-sectional study. Front Neurol. 2022;13:988677.
- Mulugeta H, et al. Magnitude, risk factors and outcomes of stroke at Debre Markos Referral Hospital, Northwest Ethiopia: a retrospective observational study. Egypt J Neurol Psychiatry Neurosurg. 2020;56:1–9.
- Abdu H, Seyoum G, Tadese F. Clinical Profiles, Risk Factors and In-hospital Outcomes of Stroke in the Medical Ward of Dessie Comprehensive Specialized Hospital, Northeast Ethiopia; A retrospective study. 2022.
- Erkabu SG, et al. Ischemic and hemorrhagic stroke in Bahir Dar, Ethiopia: a retrospective hospital-based study. J Stroke Cerebrovasc Dis. 2018;27(6):1533–8.
- Abdella SG et al. Clinical profile, in-hospital outcome and associated factors of stroke after the start of a standard organized stroke care unit at university of Gondar hospital, northwest Ethiopia. 2019.
- Mulat B, et al. Magnitude of stroke and associated factors among patients who attended the medical ward of Felege Hiwot Referral Hospital, Bahir Dar town, Northwest Ethiopia. Ethiop J Health Dev. 2016;30(3):129–34.
- Zewdie A, et al. Prospective assessment of patients with stroke in Tikur Anbessa specialised hospital, Addis Ababa, Ethiopia. Afr J Emerg Med. 2018;8(1):21–4.
- 42. Asres AK, et al. Frequency, nursing managements and stroke patients' outcomes among patients admitted to Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia a retrospective, institution based cross-sectional study. Int J Afr Nurs Sci. 2020;13:100228.
- Gedefa B, et al. Assessment of risk factors and treatment outcome of stroke admissions at St. Paul's Teaching Hospital, Addis Ababa, Ethiopia. J Neurol Neurophysiol. 2017;8(3):1–6.
- Sultan M, et al. Epidemiology of stroke patients in Tikur Anbessa specialized hospital: emphasizing clinical characteristics of hemorrhagic stroke patients. Ethiop J Health Dev. 2017;31(1):13–7.
- 45. Mamushet Y, Zenebe G, Addissie A. Medical and neurological complications among stroke patients admitted for inpatient care in Addis Ababa, Ethiopia. Ethiop Med J. 2015;53(1):9–17.

- Zewudie AZ et al. Treatment Outcome and Its Determinants among Patients Admitted to Stroke Unit of Jimma University Medical Center, Southwest Ethiopia. Stroke research and treatment, 2020. 2020.
- 47. Kefale B et al. Management practice, and treatment outcome and its associated factors among hospitalized stroke patient at Ambo University Referral Hospital, Ethiopia: an Institutional Based Cross Sectional Study. 2019.
- Bekele F, et al. Magnitude and predictors of stroke treatment outcomes in low resource settings: a cross-sectional study. Int J Afr Nurs Sci. 2023;18:100558.
- Fekadu G, Chelkeba L, Kebede A. Risk factors, clinical presentations and predictors of stroke among adult patients admitted to stroke unit of Jimma university medical center, south west Ethiopia: prospective observational study. BMC Neurol. 2019;19(1):1–11.
- Beyene D, Asefa H. A two year retrospective cross-sectional study on prevalence, associated factors and treatment outcome among patients admitted to medical ward (stroke unit) at Jimma University Medical Center, Jimma, South West, Ethiopia, 2018. Palliat Med Care. 2018;5(4):1–6.
- Mosisa W et al. Survival status and predictors of mortality among adult stroke patients admitted to Jimma University Medical Center, South West Ethiopia: a retrospective cohort study. Vasc Health Risk Manag, 2023: pp. 527–41.
- 52. Gidey K, Hailu A. A prospective study of stroke characteristics, risk factors, and Mortality in a Tertiary Hospital of Northern Ethiopia. Int J Gen Med, 2023: pp. 5051–61.
- Gebremariam SA, Yang HS. Types, risk profiles, and outcomes of stroke patients in a tertiary teaching hospital in northern Ethiopia. ENeurologicalSci. 2016;3:41–7.
- 54. Asgedom SW, et al. Medical complications and mortality of hospitalized stroke patients. J Stroke Cerebrovasc Dis. 2020;29(8):104990.
- 55. Deresse B, Shaweno D. Epidemiology and in-hospital outcome of stroke in South Ethiopia. J Neurol Sci. 2015;355(1–2):138–42.
- Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–8.
- Pan Y, et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and metaanalysis. Circulation. 2017;135(1):21–33.
- Kamel H, et al. Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke. 2016;47(3):895–900.

- J'Neka SC, et al. Geographic disparities in the incidence of stroke among patients with atrial fibrillation in the United States. J Stroke Cerebrovasc Dis. 2019;28(4):890–9.
- Hernandez I, Saba S, Zhang Y. Geographic variation in the use of oral anticoagulation therapy in stroke prevention in atrial fibrillation. Stroke. 2017;48(8):2289–91.
- 61. Chew DS, et al. Geographic and temporal variation in the treatment and outcomes of atrial fibrillation: a population-based analysis of national quality indicators. Can Med Association Open Access J. 2022;10(3):E702–13.
- 62. Abate TW, et al. The burden of stroke and modifiable risk factors in Ethiopia: a systemic review and meta-analysis. PLoS ONE. 2021;16(11):e0259244.
- Rodriguez CJ, et al. Atrial fibrillation incidence and risk factors in relation to race-ethnicity and the population attributable fraction of atrial fibrillation risk factors: the multi-ethnic study of atherosclerosis. Ann Epidemiol. 2015;25(2):71–6. e1.
- 64. Desteghe L, et al. Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1394–403.
- Desteghe L, et al. Performance of handheld electrocardiogram devices to detect atrial fibrillation in a cardiology and geriatric ward setting. Ep Europace. 2017;19(1):29–39.
- 66. Yimer NS, et al. Anticoagulation control, outcomes, and associated factors in patients with atrial fibrillation receiving warfarin at tertiary care hospital in Ethiopia. Clin Appl Thromb Hemost. 2021;27:10760296211049786.
- 67. Goel D, et al. Prevalence of atrial fibrillation in acute ischemic stroke patients: a hospital-based study from India. Brain Circulation. 2020;6(1):19–25.
- Mitaine A et al. Prevalence and characteristics of known versus newly detected atrial fibrillation in ischemic stroke: a population-based study. Neuroepidemiology, 2024.
- 69. Alene M, et al. Magnitude of risk factors and in-hospital mortality of stroke in Ethiopia: a systematic review and meta-analysis. BMC Neurol. 2020;20(1):1–10.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.